Celltrion. has been granted a patent for a stable liquid pharmaceutical preparation of anti-influenza virus antibodies. This formulation includes specific concentrations of surfactants, sugars, and amino acids, demonstrating excellent storage stability across various temperatures and multiple administration routes. GlobalData’s report on Celltrion gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Celltrion, Peptide nano-particle conjugates was a key innovation area identified from patents. Celltrion's grant share as of July 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12065482B2 describes a stable liquid pharmaceutical formulation designed for the treatment of influenza, comprising a specific mixture of anti-influenza virus antibodies. The formulation includes 25 to 50 mg/mL of two or more different antibodies, a surfactant (polysorbate 80) at a concentration of 0.02 to 0.1% (w/v), sorbitol as a sugar or its derivative at 1.0 to 5% (w/v), and histidine at 5 to 15 mM. The formulation is characterized by a pH of 6 and features antibodies with defined variable regions, including specific complementarity-determining regions (CDRs) as outlined in the claims. Additionally, the antibodies are designed to bind to specific epitopes on the hemagglutinin (HA) protein of the influenza A virus.
The patent further specifies that the formulation maintains a high antibody monomer purity of 95% or greater after storage for both 6 weeks at 40±2°C and 12 months at 5±3°C. It is suitable for various administration routes, including intravenous, intramuscular, and subcutaneous methods. The patent also includes claims for a pre-filled syringe containing the formulation, an auto-injector that incorporates the syringe, and a kit that consists of the formulation and a container. This comprehensive formulation and its delivery systems aim to enhance the stability and efficacy of anti-influenza treatments.
To know more about GlobalData’s detailed insights on Celltrion, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
